ABN-401 is under clinical development by Abion and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ABN-401’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABN-401 is under development for the treatment of gastric cancer, metastatic solid tumors such as non-small cell lung cancer, melanoma, breast cancer, sarcoma, carcinoma and prostate cancer. The drug candidate is a triazolopyrazine derivative. It is administered through oral route. It acts by targeting hepatocyte growth factor receptor (HGFR) or c met.
Abion is a biopharmaceutical company. It conducts research activities to develop biopharmaceutical drugs and companion diagnostic systems for the treatment of incurable diseases. The company offers preclinical phase products such as ABN101, ABN301, ABN302, ABN401, and others. It conducts research and development to develop protein drugs, antibody therapeutics to target claudin essential proteins and siRNA therapeutics, to target E6, E7 oncogenes, and others. Abion provides drugs which find application in treating multiple sclerosis; and various cancers including cervical, lung and ovarian cancer in women. Abion is headquartered in Seoul City, Seoul, South Korea.
For a complete picture of ABN-401’s drug-specific PTSR and LoA scores, buy the report here.